The University of Chicago Header Logo

Connection

James Liao to Hydroxymethylglutaryl-CoA Reductase Inhibitors

Back to Details
This is a "connection" page, showing publications James Liao has written about Hydroxymethylglutaryl-CoA Reductase Inhibitors.
James Liao
Connection Strength
9.493
Hydroxymethylglutaryl-CoA Reductase Inhibitors
  1. Understanding the molecular mechanisms of statin pleiotropic effects. Arch Toxicol. 2023 06; 97(6):1529-1545.
    View in: PubMed
    Score: 0.584
  2. Emerging views of statin pleiotropy and cholesterol lowering. Cardiovasc Res. 2022 01 29; 118(2):413-423.
    View in: PubMed
    Score: 0.536
  3. The Pleiotropic Effects of Statins - From Coronary Artery Disease and Stroke to Atrial Fibrillation and Ventricular Tachyarrhythmia. Curr Vasc Pharmacol. 2019; 17(3):222-232.
    View in: PubMed
    Score: 0.433
  4. Pleiotropic Effects of Statins on the Cardiovascular System. Circ Res. 2017 Jan 06; 120(1):229-243.
    View in: PubMed
    Score: 0.378
  5. Evidence of pleiotropy by statins: leukocyte Rho kinase (ROCK) activity and pretreated statin before percutaneous coronary interventions are clinical vascular outcome predictors. Int J Cardiol. 2014 Sep; 176(1):250-3.
    View in: PubMed
    Score: 0.317
  6. Rho/Rho-associated coiled-coil forming kinase pathway as therapeutic targets for statins in atherosclerosis. Antioxid Redox Signal. 2014 Mar 10; 20(8):1251-67.
    View in: PubMed
    Score: 0.301
  7. Mitohormesis: another pleiotropic effect of statins? Eur Heart J. 2012 Jun; 33(11):1299-301.
    View in: PubMed
    Score: 0.262
  8. Squalene synthase inhibitor lapaquistat acetate: could anything be better than statins? Circulation. 2011 May 10; 123(18):1925-8.
    View in: PubMed
    Score: 0.254
  9. Pleiotropic effects of statins. - Basic research and clinical perspectives -. Circ J. 2010 May; 74(5):818-26.
    View in: PubMed
    Score: 0.237
  10. Statins and cardiovascular diseases: from cholesterol lowering to pleiotropy. Curr Pharm Des. 2009; 15(5):467-78.
    View in: PubMed
    Score: 0.217
  11. Comparison of effects of rosuvastatin (10 mg) versus atorvastatin (40 mg) on rho kinase activity in caucasian men with a previous atherosclerotic event. Am J Cardiol. 2009 Feb 15; 103(4):437-41.
    View in: PubMed
    Score: 0.216
  12. Additive effects of statin and dipyridamole on cerebral blood flow and stroke protection. J Cereb Blood Flow Metab. 2008 Jul; 28(7):1285-93.
    View in: PubMed
    Score: 0.206
  13. Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med. 2008 Jan; 14(1):37-44.
    View in: PubMed
    Score: 0.202
  14. Does it matter whether or not a lipid-lowering agent inhibits Rho kinase? Curr Atheroscler Rep. 2007 Nov; 9(5):384-8.
    View in: PubMed
    Score: 0.200
  15. Safety and efficacy of statins in Asians. Am J Cardiol. 2007 Feb 01; 99(3):410-4.
    View in: PubMed
    Score: 0.188
  16. Recurrent Symptomatic Hemorrhage in Cerebral Cavernous Malformations After Discontinuation of Atorvastatin or Placebo. J Am Heart Assoc. 2026 02 03; 15(3):e46943.
    View in: PubMed
    Score: 0.177
  17. Rho GTPases, statins, and nitric oxide. Circ Res. 2005 Dec 09; 97(12):1232-5.
    View in: PubMed
    Score: 0.175
  18. Clinical implications for statin pleiotropy. Curr Opin Lipidol. 2005 Dec; 16(6):624-9.
    View in: PubMed
    Score: 0.175
  19. Drug Insight: statins and stroke. Nat Clin Pract Cardiovasc Med. 2005 Nov; 2(11):576-84.
    View in: PubMed
    Score: 0.174
  20. Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition beyond low-density lipoprotein cholesterol. Am J Cardiol. 2005 Sep 05; 96(5A):24F-33F.
    View in: PubMed
    Score: 0.172
  21. Safety and efficacy of atorvastatin for rebleeding in cerebral cavernous malformations (AT CASH EPOC): a phase 1/2a, randomised placebo-controlled trial. Lancet Neurol. 2025 Apr; 24(4):295-304.
    View in: PubMed
    Score: 0.167
  22. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol. 2005; 45:89-118.
    View in: PubMed
    Score: 0.164
  23. Statins: potent vascular anti-inflammatory agents. Int J Clin Pract Suppl. 2004 Oct; (143):41-8.
    View in: PubMed
    Score: 0.161
  24. Statins and myocardial hypertrophy. Coron Artery Dis. 2004 Aug; 15(5):247-50.
    View in: PubMed
    Score: 0.160
  25. Statin therapy: having the good without the bad. Hypertension. 2004 Jun; 43(6):1171-2.
    View in: PubMed
    Score: 0.158
  26. Statin therapy for cardiac hypertrophy and heart failure. J Investig Med. 2004 May; 52(4):248-53.
    View in: PubMed
    Score: 0.157
  27. Lipid management with statins. The lower the better? Z Kardiol. 2004 Jan; 93(1):4-9.
    View in: PubMed
    Score: 0.153
  28. Isoprenoid metabolism and the pleiotropic effects of statins. Curr Atheroscler Rep. 2003 Sep; 5(5):372-8.
    View in: PubMed
    Score: 0.150
  29. Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation. 2003 Aug 19; 108(7):839-43.
    View in: PubMed
    Score: 0.149
  30. Endothelium-dependent effects of statins. Arterioscler Thromb Vasc Biol. 2003 May 01; 23(5):729-36.
    View in: PubMed
    Score: 0.144
  31. Rapid effects of statins: from prophylaxis to therapy for ischemic stroke. Arterioscler Thromb Vasc Biol. 2003 Feb 01; 23(2):156-7.
    View in: PubMed
    Score: 0.144
  32. A novel pleiotropic effect of statins: prevention of cardiac hypertrophy by cholesterol-independent mechanisms. Ann Med. 2003; 35(6):398-403.
    View in: PubMed
    Score: 0.143
  33. Beyond lipid lowering: the role of statins in vascular protection. Int J Cardiol. 2002 Nov; 86(1):5-18.
    View in: PubMed
    Score: 0.141
  34. Isoprenoids as mediators of the biological effects of statins. J Clin Invest. 2002 Aug; 110(3):285-8.
    View in: PubMed
    Score: 0.139
  35. Statins and ischemic stroke. Atheroscler Suppl. 2002 May; 3(1):21-5.
    View in: PubMed
    Score: 0.136
  36. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol. 2001 Nov; 21(11):1712-9.
    View in: PubMed
    Score: 0.132
  37. Challenging Statin Pleiotropy: Preeclampsia. Circulation. 2021 08 31; 144(9):680-683.
    View in: PubMed
    Score: 0.130
  38. Direct vascular effects of HMG-CoA reductase inhibitors. Trends Cardiovasc Med. 2000 May; 10(4):143-8.
    View in: PubMed
    Score: 0.119
  39. 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27(Kip1). J Biol Chem. 1999 Jul 30; 274(31):21926-31.
    View in: PubMed
    Score: 0.113
  40. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci U S A. 1998 Jul 21; 95(15):8880-5.
    View in: PubMed
    Score: 0.105
  41. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation. 1998 Mar 31; 97(12):1129-35.
    View in: PubMed
    Score: 0.103
  42. Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase. J Biol Chem. 1997 Dec 12; 272(50):31725-9.
    View in: PubMed
    Score: 0.101
  43. Statins exert the pleiotropic effects through small GTP-binding protein dissociation stimulator upregulation with a resultant Rac1 degradation. Arterioscler Thromb Vasc Biol. 2013 Jul; 33(7):1591-600.
    View in: PubMed
    Score: 0.073
  44. Pitavastatin-induced angiogenesis and arteriogenesis is mediated by Notch1 in a murine hindlimb ischemia model without induction of VEGF. Lab Invest. 2011 May; 91(5):691-703.
    View in: PubMed
    Score: 0.063
  45. Rho-associated coiled-coil-forming kinases (ROCKs): potential targets for the treatment of atherosclerosis and vascular disease. Trends Pharmacol Sci. 2011 Mar; 32(3):167-73.
    View in: PubMed
    Score: 0.062
  46. Targeting eNOS and beyond: emerging heterogeneity of the role of endothelial Rho proteins in stroke protection. Expert Rev Neurother. 2009 Aug; 9(8):1171-86.
    View in: PubMed
    Score: 0.056
  47. Rho kinase: an important mediator of atherosclerosis and vascular disease. Curr Pharm Des. 2009; 15(27):3108-15.
    View in: PubMed
    Score: 0.054
  48. Statins inhibit Rho kinase activity in patients with atherosclerosis. Atherosclerosis. 2009 Aug; 205(2):517-21.
    View in: PubMed
    Score: 0.054
  49. Simvastatin reverses cardiac hypertrophy caused by disruption of the bradykinin 2 receptor. Can J Physiol Pharmacol. 2008 Sep; 86(9):633-42.
    View in: PubMed
    Score: 0.053
  50. Phosphatidylinositol 3-kinase/protein kinase Akt negatively regulates plasminogen activator inhibitor type 1 expression in vascular endothelial cells. Am J Physiol Heart Circ Physiol. 2007 Apr; 292(4):H1937-42.
    View in: PubMed
    Score: 0.047
  51. Simvastatin decreases IL-6 and IL-8 production in epithelial cells. J Dent Res. 2006 Jun; 85(6):520-3.
    View in: PubMed
    Score: 0.045
  52. Protective effects of statins involving both eNOS and tPA in focal cerebral ischemia. J Cereb Blood Flow Metab. 2005 Jun; 25(6):722-9.
    View in: PubMed
    Score: 0.042
  53. Atorvastatin restores endothelial function in normocholesterolemic smokers independent of changes in low-density lipoprotein. Circ Res. 2004 Jul 23; 95(2):217-23.
    View in: PubMed
    Score: 0.039
  54. Statin therapy is associated with improved patency of autogenous infrainguinal bypass grafts. J Vasc Surg. 2004 Jun; 39(6):1178-85.
    View in: PubMed
    Score: 0.039
  55. Targeting eNOS for stroke protection. Trends Neurosci. 2004 May; 27(5):283-9.
    View in: PubMed
    Score: 0.039
  56. Simvastatin preserves cardiac function in genetically determined cardiomyopathy. J Cardiovasc Pharmacol. 2004 Mar; 43(3):454-61.
    View in: PubMed
    Score: 0.039
  57. Preservation of NO production by statins in the treatment of heart failure. Cardiovasc Res. 2003 Nov 01; 60(2):250-8.
    View in: PubMed
    Score: 0.038
  58. Long-term statin use and psychological well-being. J Am Coll Cardiol. 2003 Aug 20; 42(4):690-7.
    View in: PubMed
    Score: 0.037
  59. Acute reduction of myocardial infarct size by a hydroxymethyl glutaryl coenzyme A reductase inhibitor is mediated by endothelial nitric oxide synthase. J Cardiovasc Pharmacol. 2003 Mar; 41(3):474-80.
    View in: PubMed
    Score: 0.036
  60. Mevastatin, an HMG-CoA reductase inhibitor, reduces stroke damage and upregulates endothelial nitric oxide synthase in mice. Stroke. 2001 Apr; 32(4):980-6.
    View in: PubMed
    Score: 0.032
  61. Suppression of endothelial nitric oxide production after withdrawal of statin treatment is mediated by negative feedback regulation of rho GTPase gene transcription. Circulation. 2000 Dec 19; 102(25):3104-10.
    View in: PubMed
    Score: 0.031
  62. Targeting Rho in cardiovascular disease. Circ Res. 2000 Sep 29; 87(7):526-8.
    View in: PubMed
    Score: 0.031
  63. Rho Kinase Inhibition Blunts Lesion Development and Hemorrhage in Murine Models of Aggressive Pdcd10/Ccm3 Disease. Stroke. 2019 03; 50(3):738-744.
    View in: PubMed
    Score: 0.027
  64. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem. 1998 Sep 11; 273(37):24266-71.
    View in: PubMed
    Score: 0.027
  65. [New findings on the action of HMG-CoA-reductase inhibitors]. Dtsch Med Wochenschr. 1997 Oct 10; 122(41):1255-9.
    View in: PubMed
    Score: 0.025
  66. RhoA Kinase Inhibition With Fasudil Versus Simvastatin in Murine Models of Cerebral Cavernous Malformations. Stroke. 2017 01; 48(1):187-194.
    View in: PubMed
    Score: 0.023
  67. Endothelial nitric oxide synthase-dependent cerebral blood flow augmentation by L-arginine after chronic statin treatment. J Cereb Blood Flow Metab. 2000 Apr; 20(4):709-17.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.